This mutation is rare in AML (<5%) however present approximately 22%–29% of the time in CBF mutations (i.e., AML harboring t(8;21)(q22;q22) or inv(16)(p13.1q22) or corresponding respective fusion genes RUNX1/RUNX1T1 and CBFB/MYH11).KIT mutations have been shown to confer higher relapse risk and lower OS. This evidence concerns the gene CEBPZ and acute myeloid leukemia.